<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24498">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02787837</url>
  </required_header>
  <id_info>
    <org_study_id>CNI-ABI-2014-02</org_study_id>
    <secondary_id>CNIO-CP-03-2014</secondary_id>
    <nct_id>NCT02787837</nct_id>
  </id_info>
  <brief_title>PROSABI: Prospective Multi-centre Study of Prognostic Factors in CRPC Treated With Abiraterone</brief_title>
  <acronym>PROSABI</acronym>
  <official_title>Prospective Multi-centre Studies of Prognostic Factors in Castration Resistant PROState Cancer Treated With Abiraterone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Nacional de Investigaciones Oncologicas CARLOS III</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Nacional de Investigaciones Oncologicas CARLOS III</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective Multi-centre Studies of Prognostic Factors in Castration resistant PROState
      Cancer Treated With Abiraterone (PROSABI)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic value for global survival</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Independently validate the prognostic value for global survival of the expression signature in peripheral blood of nine genes characterised by Olmos et al. (Lancet Oncol., 2012) in two cohorts of patients with castration-resistant prostate cancer (CRPC) who are candidates for treatment with abiraterone acetate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prognostic value for the progression-free survival</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Analyse the prognostic value for the progression-free survival (PSA and radiological) of the expression signature described by Olmos et al. (Lancet Oncol., 2012). Increased PSA units (ng/mL) and radiologic according RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global survival of the early changes</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Study the prognostic value for global survival of the early changes (prior to receiving the third cycle of treatment) in expression signatures described by Olmos et al. (Lancet Oncol., 2012).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic value for global survival</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Evaluate the prognostic value for global survival (PSA and radiological) of the early changes in expression signatures described by Olmos et al. (Lancet Oncol., 2012). Increased PSA units (ng/mL) and radiologic according RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic and predictive utility of the expression signature</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Compare the prognostic and predictive utility of the expression signature described by Olmos et al. (Lancet Oncol., 2012) with that described by Ross et al., (Lancet Oncol., 2012).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic nomograms described for CRPC</measure>
    <time_frame>through study completion, an average of 2 years</time_frame>
    <description>Validate in this patient cohorts treated with abiraterone, the prognostic nomograms described for CRPC in terms of the clinical, pathological and analytical variables recognised and recorded in the study.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Abiraterone pre</arm_group_label>
    <description>Pre-chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Abiraterone post</arm_group_label>
    <description>Post-chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>Treatment with Abiraterone 250 mg/d oral</description>
    <arm_group_label>Abiraterone pre</arm_group_label>
    <arm_group_label>Abiraterone post</arm_group_label>
    <other_name>ZYTIGA</other_name>
    <other_name>Abiraterone acetate</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      PAXgene and TEMPUS tubes at baseline, precycle 3 and progression
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Castration resistant Prostate Cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provision of informed consent.

          2. Eighteen years of age or older.

          3. General health status acceptable and compatible with active treatment: ECOG ≤0-2.

          4. Histological confirmation of prostate cancer diagnosis.

          5. Prior resistance to biochemical castration with an LHRH agonist (or surgical
             castration through bilateral orchiectomy) and progression to an anti-androgen drug
             (e.g. bicalutamide, nilutamide or cyproterone acetate).

          6. Biochemical progression upon prior treatment in agreement with PSAWG2 criteria,
             confirmed by a second PSA test.

          7. Castrate levels of testosterone in peripheral blood: testosterone &lt;0.5 ng/ml.

          8. Candidates for standard treatment with abiraterone acetate: 1000 mg every 24 h plus
             prednisone (5 mg/12 h).

          9. Availability of anatomopathological tumour material (e.g. a paraffin block of the
             prostatectomy or initial biopsy of the metastasis).

         10. Acceptable hematological, hepatic and renal functions and without contraindications
             for the administration of abiraterone in agreement with its respective summary of
             products characteristics.

        Exclusion Criteria:

          1. Previous cancer diagnosis, except those patients who had a localized malignant tumour
             and who are five years cancer-free, as well as subjects with a history of skin
             cancers (of non-melanoma type) or excised in situ carcinomas.

          2. Medical histories, be they psychiatric or of any other character, which, according to
             the judgement of the investigator, might interfere with the subject's granting of
             informed consent or the safe execution of the procedures required in the study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Olmos</last_name>
    <role>Study Chair</role>
    <affiliation>Centro Nacional de Investigaciones Oncológicas</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David Olmos, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2950</phone_ext>
    <email>dolmos@cnio.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nuria R, MD</last_name>
    <phone>34 91 732 8000</phone>
    <phone_ext>2951</phone_ext>
    <email>prostac@cnio.es</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>A Coruña</state>
        <zip>15405</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Afonso, MD</last_name>
      <phone>+34981334000</phone>
      <email>Franciso.Javier.Afonso.Afonso@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Urbano Anido, MD</last_name>
      <phone>+34981950000</phone>
      <email>urbanoanido@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO L'Hospitalet</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep M. Piulats, MD</last_name>
      <phone>+34932607780</phone>
      <email>jmpiulats@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Montserrat Domenech, MD</last_name>
      <phone>+34938759300</phone>
      <phone_ext>3309</phone_ext>
      <email>mdomenech@althaia.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Especialidades de Jerez de la Frontera</name>
      <address>
        <city>Jerez de la Frontera</city>
        <state>Cádiz</state>
        <zip>11407</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Viciana, MD</last_name>
      <phone>+34956032075</phone>
      <email>ruthvician@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Málaga</state>
        <zip>29603</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Villatoro, MD</last_name>
      <phone>+34951976470</phone>
      <email>villatororoldan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>La Laguna</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosa Delia Garcia, MD</last_name>
      <phone>+34922678204</phone>
      <email>rdgmarrero@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Burgos</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillermo Crespo, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact>
    <contact_backup>
      <last_name>Ricardo Sanchez, MD</last_name>
      <phone>+34947281978</phone>
      <email>rescribano@seom.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Ciudad Real</name>
      <address>
        <city>Ciudad Real</city>
        <zip>13005</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Carlos Villa, MD</last_name>
      <phone>+34926278000</phone>
      <phone_ext>77137</phone_ext>
      <email>jvillaguzman1@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Jose Mendez, MD</last_name>
      <phone>+34957011147</phone>
      <email>mjosemv@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen de las Nieves</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Luque, MD</last_name>
      <phone>+34958020000</phone>
      <email>rluquecaro@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Casinello, MD</last_name>
      <phone>+34949209200</phone>
      <email>jacaes@sescam.jccm.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Angel Arranz, MD</last_name>
      <phone>+34914269070</phone>
      <email>jarranz@oncomed.gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Coordination PROCURE-Centro Nacional de Investigaciones Oncologicas</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nuria Romero, MD</last_name>
      <phone>347328000</phone>
      <phone_ext>2951</phone_ext>
      <email>nromerol@cnio.es</email>
    </contact>
    <contact_backup>
      <last_name>Berta Nasarre, PhD</last_name>
      <email>bnasarre@cnio.es</email>
    </contact_backup>
    <investigator>
      <last_name>Leticia Rivera, CRA senior</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gala Grau, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Isabel Pacheco, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teresa Garces, Technician</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier Puente, MD</last_name>
      <phone>+34913303000</phone>
      <phone_ext>7332</phone_ext>
      <email>docjavip@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Castellanos, MD</last_name>
      <phone>+34913908339</phone>
      <email>cdanicas@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncologico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elena Castro, MD</last_name>
      <phone>+34917328000</phone>
      <phone_ext>2950</phone_ext>
      <email>ecastro@hmhospitales.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Madrid Sanchinarro</name>
      <address>
        <city>Madrid</city>
        <zip>28660</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JF Rodríguez Moreno, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Anatomical Pathology PROCURE-PROSABI</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Pacheco</last_name>
      <phone>+34951032000</phone>
      <email>misabel.pacheco.sspa@juntadeandalucia.es</email>
    </contact>
    <investigator>
      <last_name>Maria Pilar Gonzalez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario Virgen de la Victoria</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Isabel Medina, MD</last_name>
      <phone>+34951291425</phone>
      <email>msaez.med@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Morales Messeguer</name>
      <address>
        <city>Murcia</city>
        <zip>30008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Gonzalez, MD</last_name>
      <phone>+34968360900</phone>
      <phone_ext>3807</phone_ext>
      <email>engonbil@um.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aranzazu Gonzalez, MD</last_name>
      <phone>+34871206130</phone>
      <phone_ext>76130</phone_ext>
      <email>aranzazu.gonzalezdealba@ssib.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Pontevedra</name>
      <address>
        <city>Pontevedra</city>
        <zip>36002</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cristina Azpitarte, MD</last_name>
      <phone>+34 986800004</phone>
      <email>crisazpi@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Lorente, MD</last_name>
      <phone>+34961244000</phone>
      <email>davlorente@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 26, 2017</lastchanged_date>
  <firstreceived_date>October 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prognostic</keyword>
  <keyword>Castration</keyword>
  <keyword>Resistant</keyword>
  <keyword>Abiraterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
